Bristol-Myers Squibb Company (BMY) Stock

NYSE: BMYGlobal biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for serious diseases.

Bristol Myers Squibb stock price chart

BMY interactive chart →

BMY stock quote & key statistics

Bristol Myers Squibb earnings per share

Income →
Earnings per share

Bristol Myers Squibb revenue & net income

Income →
RevenueNet income

Bristol Myers Squibb annual financials

Income statement →
Fiscal yearRevenueNet incomeEPS
FY2025$48.20B$7.05B$6.15
FY2024$48.30B-$8.95B$1.14
FY2023$45.01B$8.03B$7.39
FY2022$46.16B$6.33B$7.70
FY2021$46.38B$6.99B$7.50

Fiscal year ending December 31. Source: company filings via EODHD.

About Bristol-Myers Squibb Company

Bristol-Myers Squibb Company is a global biopharmaceutical leader engaged in the discovery, development, licensing, manufacturing, and marketing of innovative medicines. With a diverse portfolio spanning hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and COVID-19 diseases, the company is dedicated to addressing critical medical needs worldwide. Key products include Revlimid for multiple myeloma, Eliquis for stroke prevention and DVT/PE treatment, Opdivo for anti-cancer therapy, and Pomalyst/Imnovid for multiple myeloma patients.

Additionally, Bristol-Myers Squibb offers a range of treatments such as Orencia for rheumatoid arthritis, Sprycel for chronic myeloid leukemia, Yervoy for melanoma, and Abraxane for chemotherapy. The company's innovative pipeline includes Reblozyl for beta thalassemia-related anemia, Empliciti for multiple myeloma, Zeposia for multiple sclerosis, Breyanzi for large B-cell lymphoma, Inrebic for myelofibrosis, and Onureg for acute myeloid leukemia.

Founded in 1887 and headquartered in New York, New York, Bristol-Myers Squibb serves a broad customer base including wholesalers, distributors, pharmacies, hospitals, clinics, retailers, and government agencies. Formerly known as Bristol-Myers Company, the company's commitment to advancing healthcare through groundbreaking therapies underscores its position as a leader in the biopharmaceutical industry, continuously striving to improve patient outcomes worldwide.

Bristol Myers Squibb stock FAQ

What is the Bristol Myers Squibb stock ticker symbol?

Bristol-Myers Squibb Company trades on the NYSE under the ticker symbol BMY.

What sector and industry is Bristol Myers Squibb in?

Bristol-Myers Squibb Company is classified in the Healthcare sector, Drug Manufacturers - General industry.

How many employees does Bristol Myers Squibb have?

Bristol-Myers Squibb Company has about 32,500 full-time employees.

What were Bristol Myers Squibb's revenue and earnings last fiscal year?

Bristol Myers Squibb reported revenue of $48.20B and net income of $7.05B in fiscal 2025, with earnings per share of $6.15. Revenue declined 0.2% from the prior year.

Is Bristol Myers Squibb in the S&P 500?

Yes. Bristol-Myers Squibb Company (BMY) is a component of the S&P 500, the index of 500 leading U.S. companies widely used as a benchmark for the U.S. stock market.

Is Bristol Myers Squibb in the Russell 1000?

Yes. Bristol-Myers Squibb Company (BMY) is a component of the Russell 1000, which tracks roughly the 1,000 largest U.S. companies.

S&P 500 Healthcare stocks

All S&P 500 →